Skip to content
HabitSeek
Back to results

Eat enough fibre from foods

Eating fibre-rich foods such as whole grains, pulses, fruit and vegetables as a regular part of the diet.

At a glance

  • Evidence: Higher food-fibre intake is associated with lower rates of major disease.Death and major disease incidence · Moderate certainty · Observational association
  • What’s uncertain: Cooling starch does not establish weight loss or reproduce every supplement trial.
  • First step: Increase fibre-rich foods gradually from your current intake.
  • Before you try it: Increase gradually and get dietary advice for bowel conditions or a restricted diet. All precautions
Read the full takeaway

Prospective cohort findings

Higher dietary fibre intake is associated with lower rates of cardiovascular disease, type 2 diabetes, colorectal cancer and death in large prospective syntheses.

Randomized trials

Randomised trials support improvements in some risk factors, not a proven reduction in clinical events: the pooled fibre trials lowered body weight, systolic blood pressure and total cholesterol, and whole-grain substitution improved LDL cholesterol, triglycerides, HbA1c and C-reactive protein while one crossover trial found no effect on glucose homeostasis or the microbiome, and the whole-grain review's own conclusion was that the evidence is insufficient for a cardiovascular recommendation.

Colorectal cancer findings

An independent UK Biobank cohort published after the Reynolds review found lower colorectal cancer risk for fibre from bread and breakfast cereals, but its total-fibre estimate crossed the null and fruit and vegetable fibre were not associated with risk.

Interpreting the intake range

The 25–29 g/day range is the intake at which risk reduction was greatest in the cohort analyses; it is an observed range, not an upper limit or a target ceiling, and the review reports that higher intakes could confer greater benefit rather than harm.

Oats being poured into a bowlDiscussed by4 peopleView statements ↓
NutritionLong-term healthVaries · Moderate · Low
Reviewed Oct 3, 2026
Save

Scientific evidence

What the research shows

Outcome assessments based on research, including its uncertainties and limitations.

Death and major disease incidence

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: observational studies (association, not proof of cause)

Comparing the highest with the lowest fibre consumers, observational data suggest the risk of all-cause and cardiovascular mortality and of several major diseases was 15 to 30 percent lower.

Population: Adults without chronic disease in the review's 185 prospective studies and 58 clinical trials (4,635 participants; just under 135 million person-years), a programme that covered dietary fibre, whole grains and glycaemic index and load, of which the dietary-fibre analyses are the subset relevant here. Weight-loss trials, supplement trials and studies of people with existing chronic disease were excluded. The independent UK Biobank cohort followed 475,581 adults aged 40-69 for an average of 5.7 years.

Research details

Summary

A series of systematic reviews and meta-analyses covering just under 135 million person-years of data from 185 prospective studies and 58 clinical trials with 4,635 adult participants found that observational data suggest a 15 to 30 percent decrease in all-cause and cardiovascular related mortality, and in the incidence of coronary heart disease, stroke incidence and mortality, type 2 diabetes, and colorectal cancer, when comparing the highest dietary fibre consumers with the lowest. Risk reduction across critical outcomes was greatest when daily intake of dietary fibre was between 25 g and 29 g, and dose-response curves suggested that higher intakes could confer even greater benefit against cardiovascular diseases, type 2 diabetes, and colorectal and breast cancer. The authors graded the certainty of evidence for dietary fibre as moderate. The 185 studies and 58 clinical trials are the totals for the whole carbohydrate-quality programme, which also covered whole grains and glycaemic index and load, so the dietary-fibre analyses are a subset of that dataset rather than the whole of it. In an independent UK Biobank cohort published after this review, the highest fifth of fibre intake from bread and breakfast cereals had a 14% lower colorectal cancer risk (95% CI 2–24%) than the lowest fifth. The full paper also reports HR 0.94 (95% CI 0.86–1.03) per 5 g/day higher total fibre, with an interval crossing the null; fruit and vegetable fibre were not associated with risk. The cereal and bread fibre finding is the part of this entry that is corroborated independently: it points the same way as the pooled cohort evidence for fibre as a whole, it is the food source the wider literature most consistently associates with lower colorectal cancer risk, and the whole-grain randomised trials in the third outcome below report improvements in LDL cholesterol, triglycerides, HbA1c and C-reactive protein. The estimates that are not corroborated are the total-fibre estimate, whose confidence interval crosses the null in this cohort, and fruit and vegetable fibre, which showed no association with colorectal cancer here. Wholegrain constituents other than fibre could explain part of the association, which is also why the trials replacing refined grain with whole grain are relevant to a fibre entry.

Why this certainty

Rated Moderate, matching the GRADE assessment the review itself reports for dietary fibre. Certainty is not higher because the outcome data are observational even though the dataset is unusually large and the dose-response gradient is consistent. Certainty is not lower because the findings are complementary across cohorts and trials, the dose-response relationship is striking, and the trial evidence independently shows improvements in body weight, systolic blood pressure and total cholesterol, which the review's authors interpreted as compatible with a causal relationship for the cohort findings; that is their interpretation of observational data, not a randomised demonstration of fewer clinical events. The later UK Biobank cohort adds independent participants but its null-compatible total-fibre estimate and food-source differences limit generalization. This qualifies the colorectal claim without changing the broader review-based Moderate rating.

Limitations

The disease and mortality estimates come from prospective cohorts, so they describe associations and cannot establish that raising fibre intake lowers risk by the stated amount; people who eat more fibre differ in many other ways. The authors graded the certainty only moderate. The range 25 g to 29 g per day is the intake at which risk reduction was greatest in these analyses, not a threshold derived from a randomised trial of disease outcomes. The review excluded people with chronic disease, so it does not describe secondary prevention, and it excluded supplement trials, so it says nothing about fibre supplements. In the later UK Biobank cohort, cereal and bread fibre was independently associated with lower colorectal cancer risk while total fibre had a confidence interval crossing the null and fruit and vegetable fibre showed no association, so only the cereal and bread part of the food-source picture is independently corroborated. Cereal and bread fibre may track wholegrain constituents rather than fibre itself, and the authors could not adjust for total energy intake. The 25 g to 29 g per day range is where risk reduction was greatest in these cohorts; it is not a ceiling, and nothing in the cited evidence suggests that eating 30 g per day or more is harmful - the review reports that higher intakes could confer greater benefit.

Effect estimate

15-30% lower risk of all-cause and cardiovascular mortality, coronary heart disease, stroke incidence and mortality, type 2 diabetes and colorectal cancer incidence, comparing highest with lowest dietary fibre consumers, with greatest risk reduction at 25-29 g per day. The review's full series covered 185 prospective studies and 58 clinical trials with 4,635 participants across dietary fibre, whole grains and glycaemic index/load; the dietary-fibre analyses are a subset.

Sources for this outcome:

Body weight, blood pressure and cholesterol

Finding: Benefit supportedCertainty: Moderatestudies found a benefit from doing this

Evidence basis: randomised trials

Randomised trials found significantly lower bodyweight, systolic blood pressure and total cholesterol with higher dietary fibre intake.

Population: 4,635 adult participants across the 58 randomised clinical trials of the whole carbohydrate-quality series, which covered dietary fibre, whole grains and glycaemic index/load; the dietary-fibre trial analyses are a subset of that total, and the review excluded weight-loss trials and trials involving fibre supplements by design.

Research details

Summary

Within the same systematic review and meta-analysis programme, pooled randomised controlled trials showed significantly lower bodyweight, systolic blood pressure, and total cholesterol when comparing higher with lower intakes of dietary fibre. These were risk-factor outcomes measured in trials rather than disease events, and they provide the interventional support for the observational associations seen in the cohort data.

Why this certainty

Rated Moderate. Randomised allocation removes confounding within these comparisons, a genuine strength over the cohort data. Certainty is held at Moderate rather than Strong because the endpoints are surrogate risk factors rather than disease outcomes, the trials were heterogeneous in intervention and duration, and supplement and weight-loss trials were excluded so the estimate applies to a particular kind of trial.

Limitations

The trials measured risk factors rather than clinical events, so they show that fibre changes physiology in a favourable direction without directly demonstrating fewer heart attacks or deaths. Trials were excluded if they involved supplements or were designed for weight loss, which narrows generalisability to food-based fibre in weight-stable people. The retrieved abstract reports no magnitude for the effects on weight, blood pressure or cholesterol, so no figure is quoted here.

Sources for this outcome:

Cardiometabolic risk factors in randomised trials of fibre-rich foods

Finding: Mixed evidenceCertainty: Limitedstudies disagree, or the effect depends on who is studied

Evidence basis: randomised trials

Trials replacing refined grain with whole grain improved some lipid, glycaemic and inflammatory markers, but the same review judged the evidence insufficient for a cardiovascular recommendation.

Population: Adults in randomised controlled trials of whole grain versus refined grain: 25 trials (22 meta-analysed) lasting 2 to 16 weeks, mostly in healthy samples and mostly using mixed whole grains, plus 60 Danish adults at risk of metabolic syndrome in an eight-week crossover with at least a six-week washout. The pooled dietary-fibre trials cover 4,635 adults.

Research details

Summary

Replacing refined grains with whole grains is the most directly randomised test of a fibre-rich swap against a low-fibre comparator. A systematic review and meta-analysis with a GRADE clinical recommendation included 25 randomised controlled trials, 22 of which were meta-analysed, with interventions of 2 to 16 weeks in mostly healthy samples. Whole-grain oats lowered total cholesterol (standardised mean difference -0.54, 95% CI -0.95 to -0.12) and LDL cholesterol (SMD -0.57, 95% CI -0.84 to -0.31); whole-grain rice lowered triglycerides (SMD 0.22, 95% CI -0.44 to -0.01); and whole grains of all types lowered haemoglobin A1c (SMD -0.33, 95% CI -0.61 to -0.04) and C-reactive protein (SMD -0.22, 95% CI -0.44 to -0.00). The same review nevertheless concluded that there is insufficient evidence to recommend whole grains as opposed to refined grains for the prevention and treatment of cardiovascular disease, which is why this outcome is recorded as mixed rather than as a benefit. The wider review programme's pooled randomised trials point the same way on other risk factors, showing significantly lower body weight, systolic blood pressure and total cholesterol with higher dietary fibre intake. A separate eight-week randomised crossover in 60 adults at risk of metabolic syndrome found that a whole-grain diet did not significantly alter glucose homeostasis and produced no major change in the faecal microbiome, although it did reduce body weight and the inflammatory markers interleukin-6 and C-reactive protein. Glycaemic and lipid markers therefore do not move together, and none of these trials measured clinical events.

Why this certainty

Rated Limited and recorded as Mixed evidence. Randomised allocation removes confounding within these comparisons and several pooled estimates are statistically significant, which is a genuine strength over the cohort data. Certainty is held down because the endpoints are surrogate risk factors, the trials were short and mostly small, the same review that produced the significant lipid and glycaemic results judged the evidence insufficient to recommend whole grains over refined grains for cardiovascular prevention, and one independent crossover found no effect at all on glucose homeostasis or the microbiome. It is not rated Very limited because the randomised evidence is directly on point and its direction is consistent with the cohort findings for cereal fibre.

Limitations

These trials measure risk factors, not disease events, so they show that fibre-rich swaps change physiology in a favourable direction without demonstrating fewer heart attacks, cancers or deaths. The whole-grain review's own GRADE conclusion is that the evidence is insufficient for a cardiovascular recommendation, which sits awkwardly beside its statistically significant lipid and glycaemic results and is not explained by the retrieved abstract. Trials were short, most lasted 16 weeks or less, most samples were healthy, and the comparator was refined grain rather than a low-fibre diet in general, so the effect cannot be separated from other whole-grain constituents. The crossover trial found no effect on glucose homeostasis or the microbiome, and none of the trials measured clinical endpoints, so the surrogate nature of every estimate here is the main limit.

Effect estimate

Whole-grain oats lowered total cholesterol (SMD -0.54, 95% CI -0.95 to -0.12) and LDL cholesterol (SMD -0.57, 95% CI -0.84 to -0.31), and all whole grains lowered HbA1c (SMD -0.33, 95% CI -0.61 to -0.04) and C-reactive protein (SMD -0.22, 95% CI -0.44 to -0.00), in 22 meta-analysed randomised trials, against a review conclusion of insufficient evidence to recommend whole grains over refined grains for cardiovascular prevention.

Sources for this outcome:

Colorectal adenoma and fibre source

Finding: Benefit supportedCertainty: Limitedstudies found a benefit from doing this

Evidence basis: observational studies (association, not proof of cause)

Higher fibre intake is associated with lower risk of colorectal adenoma, the precursor lesion, and the cancer evidence is strongest for cereal fibre rather than fruit or vegetable fibre.

Population: 157,725 adults across 21 observational studies of colorectal adenoma, and ten prospective cohorts reporting every fibre source for colorectal cancer and adenoma.

Research details

Summary

A meta-analysis of 21 observational studies covering 157,725 people found a protective association between higher dietary fibre intake and colorectal adenoma (effect size 0.71, 95% CI 0.68-0.75), with moderate heterogeneity (I2 = 62.7%). A separate dose-response meta-analysis of ten prospective cohorts examined which fibre source carries the association with colorectal cancer: per 10 g/day the summary relative risk was 0.91 (95% CI 0.82-1.00) for cereal fibre, 0.95 (0.87-1.03) for vegetable fibre, 0.91 (0.78-1.06) for fruit fibre and 0.84 (0.63-1.13) for legume fibre, and for cereal fibre the association survived adjustment for folate intake (0.89, 95% CI 0.80-0.99). Its authors concluded that the evidence for colorectal cancer prevention is strongest for fibre from cereals and grains. This is the same source-specific pattern that the UK Biobank cohort in the mortality outcome reported independently, which is why the entry does not treat fibre as a single undifferentiated exposure.

Why this certainty

Rated Limited. The direction is consistent across two independent groups and across adenoma and cancer, and the cereal-fibre result is robust to folate adjustment. Certainty is not higher because every estimate is observational and therefore vulnerable to confounding by the many behaviours that track with fibre intake, because the adenoma analysis is heterogeneous, and because two of the four source-specific intervals cross the null. Certainty is not lower because the pattern replicates in a separate cohort and the dose-response gradient is present rather than absent.

Limitations

Both sources are observational, so neither establishes that raising fibre intake lowers adenoma or cancer risk. The adenoma meta-analysis found moderate heterogeneity (I2 = 62.7%) and a sex subgroup difference favouring men, and adenoma is a precursor lesion rather than a clinical endpoint, so a lower adenoma risk is not the same result as fewer cancers. In the source-specific analysis the cereal-fibre confidence interval reaches the null (1.00), the legume-fibre estimate is compatible with no association at all, and vegetable and fruit fibre dose-response curves were non-linear, so the ranking of sources is a gradient rather than a clean separation. All fibre sources were inversely associated with incident adenoma, but none was associated with recurrent adenoma.

Effect estimate

Colorectal adenoma effect size 0.71 (95% CI 0.68-0.75) for higher fibre intake across 21 studies and 157,725 people; colorectal cancer per 10 g/day cereal fibre RR 0.91 (95% CI 0.82-1.00), with vegetable 0.95 (0.87-1.03), fruit 0.91 (0.78-1.06) and legume 0.84 (0.63-1.13) fibre not clearly associated.

Sources for this outcome:

Metabolic and weight outcomes from resistant-starch interventions

Finding: Mixed evidenceCertainty: Limitedstudies disagree, or the effect depends on who is studied

Evidence basis: indirect evidence, not a direct test of this exact habit

Resistant-starch findings are mixed and do not establish weight loss.

Population: Human resistant-starch interventions with differing foods, formulations and metabolic health.

Research details

Summary

A systematic review of 11 human reports found no direct body-weight or body-composition effect. Some glucose-related markers improved, while satiety and lipid findings were inconsistent. The studies do not establish that every cooked-and-cooled food has the same effect as a concentrated starch intervention.

Why this certainty

Limited because outcomes and interventions differ and the review called for larger, longer studies. No reliable weight-loss or disease-prevention effect from cooling food is established.

Limitations

Small, varied studies and short follow-up limit clinical interpretation. Findings for starch supplements should not be transferred automatically to ordinary food preparation or the fibre-and-disease cohort evidence.

Sources for this outcome:

What people say

Who discusses this?

Public statements, with positions specific to each source and topic. These views do not determine the scientific evidence assessment.

What the research shows ↑
Show more (1)

Practical steps and precautions

How to try it

  1. Use 25–29 g/day as a useful reference range from cohort data, not a ceiling or an individually proven optimum; higher intakes may also be beneficial.
  2. Use fibre-rich foods such as whole grains, legumes, fruit and vegetables. The main disease review concerned food fibre, whereas resistant-starch supplements are a separate evidence stream.
  3. Increase gradually over a few weeks to limit bloating and gas, and drink enough fluid alongside the increase.
  4. Resistant-starch option: legumes and cooked then chilled starchy foods can add variety. Cool cooked food promptly, refrigerate it and follow ordinary safe storage and reheating guidance; this is not a proven weight-loss method or a reason to eat unsafe leftovers.

Precautions

  • If you have irritable bowel syndrome or another condition affected by fermentable carbohydrate, increase fibre with dietetic guidance rather than following a general target, because the right type of fibre differs by condition.
  • Sudden large increases in fibre commonly cause bloating, wind and cramping; these usually settle but are a reason to increase slowly rather than to abandon the change.
  • People with a history of bowel obstruction, strictures or who are awaiting bowel surgery should seek clinical advice before substantially increasing fibre.
  • If you take medication that must be absorbed predictably, ask a pharmacist before adding a large amount of concentrated fibre, because viscous fibres can slow absorption of some drugs.

References

Carbohydrate quality and human health: a series of systematic reviews and meta-analyses

Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L · Lancet (London, England) · 2019

Series of systematic reviews and meta-analyses of prospective studies and randomised controlled trialsVerified from abstract
Open original source

Diet and colorectal cancer in UK Biobank: a prospective study

Bradbury KE, Murphy N, Key TJ · International Journal of Epidemiology · 2020

Prospective UK Biobank cohort studyVerified from full text
Open original source

The Effect of Replacing Refined Grains with Whole Grains on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Clinical Recommendation

Marshall S, Petocz P, Duve E, Abbott K, Cassettari T, Blumfield M, Fayet-Moore F · Journal of the Academy of Nutrition and Dietetics · 2020

Systematic review and meta-analysis of randomized controlled trials with GRADE clinical recommendationVerified from abstract
Open original source

Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial

Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrugger S, Maerkedahl RB, Bahl MI, Lind MV, Nielsen RL, Frokiaer H, Gobel RJ, Landberg R, Ross AB, Satokari R, Sorensen SJ, Sondertoft NB, Rasmussen SS, Raun KB, Holck J, Meyer AS, Licht TR · Gut · 2019

Randomised cross-over trialVerified from abstract
Open original source

Association between Dietary Fibre Intake and Colorectal Adenoma: A Systematic Review and Meta-Analysis.

Nucci D, Fatigoni C, Salvatori T, Nardi M, Realdon S, Gianfredi V · International Journal of Environmental Research and Public Health · 2021

Systematic review and meta-analysis of observational studiesVerified from abstract
Open original source

Different dietary fibre sources and risks of colorectal cancer and adenoma: a dose-response meta-analysis of prospective studies.

Oh H, Kim H, Lee DH, Lee A, Giovannucci EL, Kang SS, Keum N · British Journal of Nutrition · 2019

Dose-response meta-analysis of prospective cohort studiesVerified from abstract
Open original source

Impact of dietary intake of resistant starch on obesity and associated metabolic profiles in human: a systematic review of the literature.

Guo J, Tan L, Kong L. · Critical reviews in food science and nutrition · 2021

Systematic reviewSystematic review of 11 human resistant-starch intervention reportsVerified from abstract
Open original source

Community

Discussion

Have you tried this? What helped or made it difficult?

Reader experiences are separate from the scientific evidence. Explore all discussions

No discussions yet.

Be the first to ask a question or share your experience.

Sign in to vote or join the discussion.

Related habits

Explore other habits in a shared category. Each has its own evidence and precautions.

Editorial history and review method

Revision 8 · Approved for publication · HabitSeek site owner (publication approval); Codex discovery audit

Prepared and checked with AI. Publication approval does not imply independent expert review. Request a correction.

Revision 4, applying the high-risk audit corrections (_report-focus-a.md plus the parent's added requirements). Changes: (1) a third outcome, randomised-cardiometabolic-risk-factors, now carries the randomised evidence on cardiometabolic risk factors, citing the parent-verified marshall-2020-refined-grain-rct (25 RCTs replacing refined grain with whole grain; oats lowered total and LDL cholesterol, whole grains lowered HbA1c and CRP) and reynolds-2019-carbohydrate-quality, plus roager-2019-wholegrain-crossover, whose null result on glucose homeostasis and the microbiome is stated as the counterweight; it is recorded as Mixed evidence/Limited because Marshall's own GRADE conclusion is that the evidence is insufficient to recommend whole grains over refined grains for cardiovascular prevention. (2) The mortality summary and limitations now state which parts are independently corroborated and which are not - the cereal and bread fibre finding is, while the total-fibre estimate crosses the null and fruit and vegetable fibre showed no association. (3) The 185-study/58-trial/4,635-participant dataset is now labelled as the whole carbohydrate-quality programme rather than as dietary fibre alone, in the summary, population and effectEstimate. (4) The 25-29 g/day range is described in the title's supporting text, the verdict, the implementation step and the limitations as an observed range of greatest risk reduction and explicitly not an upper limit, with the review's statement that higher intakes could confer greater benefit - nothing in the entry now implies that 30 g/day or more is harmful. (5) The certainty rationale attributes the causal reading to the review's authors rather than to the catalogue, and the headline uses relative-risk wording ("the risk of ... was 15 to 30 percent lower"). A second reviewer must re-check: (a) that reynolds-2022-fibre-hypertension-cvd is genuinely absent from sources.json - it was not present when this revision was written, so it was NOT added and no source was invented for the hypertension outcome; (b) the Lancet "Department of Error" for Reynolds 2019 (DOI 10.1016/S0140-6736(19)30119-9) is still unread and a human with library access must confirm it touches none of the quoted figures; (c) whether "Mixed evidence" is right for the new outcome, given that some pooled estimates are statistically significant while the review's own recommendation is that the evidence is insufficient; (d) that the new outcome's reliance on whole-grain rather than fibre-specific trials is stated clearly enough, since the entry's randomised evidence is about replacing refined grain with whole grain. Follow-up within this pass: added a fourth outcome, `colorectal-adenoma-and-source-specificity`, covering the precursor lesion and the fibre-source question, citing two independent sources (Nucci 2021 adenoma meta-analysis; Oh 2019 dose-response source analysis) plus the existing Bradbury cohort. It is a separate outcome rather than a paragraph in the mortality outcome because adenoma is a precursor lesion, not a clinical endpoint, and because the source-specific ranking would otherwise sit under a certainty label that describes mortality. A second reviewer should check that the cereal/vegetable/fruit/legume gradient is not read as a clean separation: the cereal interval reaches the null and the legume interval is uninformative. October 3 video follow-up: Added a resistant-starch food subguide and a separate Mixed/Limited assessment. Kept existing fibre disease findings separate from concentrated starch interventions. Check food-versus-supplement boundaries and food-safety wording. Publication release 2026-10-04: site owner authorized a bounded AI audit and release of this exact revision. See docs/release-audit-2026-10-04.md for source-check findings and limits. No independent health-professional or peer review is claimed. Category migration 2026-10-04: removed the separate goals field; categories: Nutrition, Long-term health → Nutrition, Long-term health. Research assessments, sources, guidance, precautions, and evidence review dates are unchanged. This revision awaits publication approval; no new evidence review is claimed. Publication approval 2026-10-04: site owner explicitly accepted all current category-migration revisions for deployment and requested that remaining limitations be retained in docs/content-review-backlog.md. Approval applies to this exact content revision. No new evidence review, independent expert review, or clinical validation is claimed; existing precautions and disclosures remain in effect. Discovery audit 2026-10-10: added familiar search aliases. Outcome assessments, evidence sources, practical guidance, precautions and evidence-review date are unchanged. Formulation aliases identify the topic covered, not an endorsement or a new effectiveness claim. This exact revision awaits publication approval. Publication approval 2026-10-10: site owner answered 'Approve and publish' to the question explicitly covering these eight naming/search revisions and deployment to habitseek.com. Approval applies to this exact revision. Evidence assessments, guidance, precautions and scientific review dates were unchanged by the discovery audit. This is publication approval, not independent expert or clinical validation. The 15 later supplement drafts are outside this approval.